Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Tazobactam is a beta-lactamase inhibitor that protects piperacillin from degradation by beta-lactamases.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
3.375 g (piperacillin 3 g / tazobactam 0.375 g) IV every 6 hours for 7-10 days; extended infusion dosing: 3.375 g IV over 4 hours every 8 hours.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Piperacillin: 0.7-1.2 hours (normal renal function), extends to 2-6 hours in renal impairment; Tazobactam: 0.8-1.2 hours (normal renal function), extends to 4-8 hours in severe renal impairment; clinically relevant for dosing interval adjustments in renal dysfunction.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Piperacillin: ~70-80% renal (glomerular filtration and tubular secretion), ~10-20% biliary; Tazobactam: ~80-85% renal, ~10% biliary; both primarily excreted unchanged in urine; small fecal elimination (<5%).
Category C
Category A/B
Electrolyte
Electrolyte